×
About 16,270 results

ALLMedicine™ Growth Hormone Center

Research & Reviews  5,342 results

Appropriate management of growth hormone deficiency during the age of transition: an It...
https://doi.org/10.1007/s40618-022-01880-w
Journal of Endocrinological Investigation; Cannavò S, Cappa M et. al.

Aug 13th, 2022 - Appropriate management of growth hormone deficiency during the age of transition: an Italian Delphi consensus statement.|2022|Cannavò S,Cappa M,Ferone D,Isidori AM,Loche S,|

Association Between Circulating CD4+ T Cell Methylation Signatures of Network-Oriented ...
https://doi.org/10.1007/s12265-022-10294-1
Journal of Cardiovascular Translational Research; Benincasa G, Maron BA et. al.

Aug 13th, 2022 - Pathogenic DNA methylation changes may be involved in pulmonary arterial hypertension (PAH) onset and its progression, but there is no data on potential associations with patient-derived hemodynamic parameters. The reduced representation bisulfite...

A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency
https://clinicaltrials.gov/ct2/show/NCT01909479

Aug 12th, 2022 - This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).

Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
https://clinicaltrials.gov/ct2/show/NCT02968004

Aug 12th, 2022 - The study will consist of a 12 month, open-label, randomized, active controlled, parallel group study comparing the efficacy and safety of weekly MOD-4023 to daily growth hormone (GH), Genotropin. After 12 months, subjects will have the option to ...

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
https://clinicaltrials.gov/ct2/show/NCT03375788

Aug 12th, 2022 - Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gl...

see more →

Guidelines  8 results

Clinical practice recommendations for growth hormone treatment in children with chronic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136166
Nature Reviews. Nephrology; Drube J, Wan M et. al.

Jun 15th, 2019 - Achieving normal growth is one of the most challenging problems in the management of children with chronic kidney disease (CKD). Treatment with recombinant human growth hormone (GH) promotes longitudinal growth and likely enables children with CKD...

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pr...
https://doi.org/10.1227/NEU.0000000000001387
Neurosurgery Fleseriu M, Bodach ME et. al.

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) ...
https://doi.org/10.1016/j.numecd.2016.02.001
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Baroni MG, Giorgino F et. al.

Feb 26th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

British Fertility Society Policy and Practice Committee: adjuvants in IVF: evidence for...
https://doi.org/10.3109/14647273.2015.985454
Human Fertility (Cambridge, England); Nardo LG, El-Toukhy T et. al.

Dec 23rd, 2014 - Optimisation of the environment favourable for satisfactory ovarian response to stimulation and successful embryo implantation remains at the core of assisted conception programmes. The evidence base for the routine use of different adjuvants, alo...

Expert consensus document: A consensus on the medical treatment of acromegaly.
https://doi.org/10.1038/nrendo.2014.21
Nature Reviews. Endocrinology; Giustina A, Chanson P et. al.

Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

see more →

Drugs  93 results see all →

Clinicaltrials.gov  756 results

A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency
https://clinicaltrials.gov/ct2/show/NCT01909479

Aug 12th, 2022 - This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).

Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
https://clinicaltrials.gov/ct2/show/NCT02968004

Aug 12th, 2022 - The study will consist of a 12 month, open-label, randomized, active controlled, parallel group study comparing the efficacy and safety of weekly MOD-4023 to daily growth hormone (GH), Genotropin. After 12 months, subjects will have the option to ...

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
https://clinicaltrials.gov/ct2/show/NCT03375788

Aug 12th, 2022 - Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gl...

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
https://clinicaltrials.gov/ct2/show/NCT05470504

Aug 12th, 2022 - STUDY DESCRIPTION The role of growth hormone (GH) in mediating pathological consequences of inadequate lipid storage will be studied in rare patient populations with high lipolysis and severe metabolic syndrome. Specifically, patients with partial...

RESIST! Blood-flow Restriction Resistance Training for Improving Insulin Sensitivity in Type 2 Diabetes
https://clinicaltrials.gov/ct2/show/NCT04222231

Aug 11th, 2022 - Type 2 diabetes (T2D) is characterized by an increasing insensitivity of muscle, fat and liver cells to the hormone insulin. About 9% of the global population is affected by this condition and mortality risk is twice as high in individuals with di...

see more →

News  294 results

Growth Hormone Therapy for Certain Children May Help Them Reach Their Potential
https://www.medscape.com/viewarticle/966890

Jan 25th, 2022 - "Dr Lilley, you'll always be my favorite doctor; you helped me grow." These were the parting words from the last patient that I treated during my endocrinology fellowship. I had watched this young man grow from a prepubertal 17-year-old to a young...

Less Burdensome Growth-Hormone Replacement With Once-Weekly Somapacitan in Children
https://www.medscape.com/viewarticle/965864

Jan 4th, 2022 - NEW YORK (Reuters Health) - For replacement of endogenous growth hormone (GH) in children with growth-hormone deficiency (GHD), a once-weekly injection of the human GH analog somapacitan was safe and effective over three years in a phase-2 randomi...

Hyperprolactinemia – When, why, and how to evaluate prolactin
https://www.mdedge.com/obgyn/article/250203/reproductive-endocrinology/hyperprolactinemia-when-why-and-how-evaluate
Mark P. Trolice, MD

Dec 23rd, 2021 - Because of the increasing popularity and success of in vitro fertilization, the field of reproductive endocrinology and infertility has steadily morphed toward the treatment of infertility. Nevertheless, a physician board certified in reproductive.

EU Green Light for Once-Weekly Growth Hormone for Kids
https://www.medscape.com/viewarticle/963032

Nov 16th, 2021 - The European Medicines Agency (EMA) has given the 'green light' to lonapegsomatropin (TransCon hGH, Ascendis Pharma), a long-acting, once-weekly formulation of human growth hormone, for growth failure in children and adolescents, aged 3 to 18 year...

FDA Approves First Once-Weekly Growth Hormone for Children
https://www.medscape.com/viewarticle/958043

Sep 2nd, 2021 - The US Food and Drug Administration (FDA) has approved lonapegsomatropin (Skytrofa, Ascendis Pharma), the first weekly subcutaneous injectable growth hormone for children with growth hormone deficiency (GHD). The approval was based on the findings...

see more →

Patient Education  15 results see all →